Dr. Jin Miao has over a decade of firsthand industry experience and extensive venture capital expertise. He joined Pulin Capital in 2020 and has long focused on the biopharmaceutical sector, with a particular emphasis on early-stage investments in cell and gene therapy (CGT). He has systematically built a portfolio around innovative drugs and cutting-edge biotechnologies, leading investments in multiple early-stage biopharmaceutical companies including Libo Biotechnology, Yuesai Biotechnology, Xizhuo Biotechnology, Lingtaike Biotechnology, and Lingbo Biotechnology.

Prior to joining Pulin Capital, Dr. Jin was deeply engaged in the industrial sector, where he worked in business development and management roles at major multinational corporations including Nikon Instruments.

Dr. Jin received his Ph.D. in Applied Life Chemistry from the University of Tokyo and holds a Master of Finance (FMBA) from the Shanghai Advanced Institute of Finance (SAIF) at Shanghai Jiao Tong University.